Camurus Overview

  • Year Founded
  • 1991

Year Founded

  • Status
  • Public

  • Employees
  • 316

Employees

  • Stock Symbol
  • CAMX

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $74.23
  • (As of Friday Closing)

Camurus General Information

Description

Camurus AB is a science-led biopharmaceutical company focused on developing and commercializing long-acting medicines for the treatment of severe and chronic diseases. It has two approved products, including treatments for opioid dependence, and a development pipeline supported by its FluidCrystal technology. Its clinical pipeline includes product candidates for conditions such as pain, cancer, endocrine, and metabolic diseases, developed in-house and in collaboration with international pharmaceutical companies. Its pipeline programs include CAM2029 for acromegaly, gastroenteropancreatic neuroendocrine tumors, and polycystic liver disease; CAM2038 for chronic pain; CAM4072 for genetic obesity disorders; CAM2043 for Raynaud's phenomenon; CAM4071 for endocrine disorders, among others.

Contact Information

Website
www.camurus.com
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • Rydbergs torg 4
  • 224 84 Lund
  • Sweden
+46 046-286
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
STO
Vertical(s)
Life Sciences
Corporate Office
  • Rydbergs torg 4
  • 224 84 Lund
  • Sweden
+46 046-286

Camurus Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Camurus Stock Performance

As of 13-Nov-2026, Camurus’s stock price is $74.23. Its current market cap is $4.42B with 59.5M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$74.23 $74.14 $46.02 - $80.11 $4.42B 59.5M 88.6K $1.35

Camurus Financials Summary

As of 30-Sep-2026, Camurus has a trailing 12-month revenue of $258M.

In Thousands,
USD 		TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 3,321,603 3,628,390 2,764,544 2,881,441
Revenue 257,933 230,579 176,588 161,524
EBITDA 98,278 90,909 45,505 50,762
Net Income 80,406 74,869 40,506 40,591
Total Assets 565,055 515,107 340,510 190,898
Total Debt 10,710 11,523 1,545 2,452
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Camurus Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Camurus‘s full profile, request access.

Request a free trial

Camurus Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Camurus AB is a science-led biopharmaceutical company focused on developing and commercializing long-acting medicines fo
Drug Discovery
Lund, Sweden
316 As of 2026

Copenhagen, Denmark
 

Luxembourg, Luxembourg
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Camurus Competitors (43)

One of Camurus’s 43 competitors is H. Lundbeck, a Corporation company based in Copenhagen, Denmark.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
H. Lundbeck Corporation Copenhagen, Denmark
Alvotech Formerly PE-Backed Luxembourg, Luxembourg
Supernus Formerly VC-backed Rockville, MD
Indivior Corporate Backed or Acquired North Chesterfield, VA
Ethypharm Private Equity-Backed Saint Cloud, France
You’re viewing 5 of 43 competitors. Get the full list »

Camurus Patents

  • 415

    Total Documents Applications and Grants

  • Total Patents Families

  • 196

    Granted

  • 32

    Pending

  • Expiring in next 12 mo

Camurus Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026125238-A1 Compositions and methods of use thereof Pending 10-Dec-2024
AU-2025264377-A1 Lipid compositions and methods of use thereof Pending 02-May-2024
WO-2025229402-A1 Lipid compositions and methods of use thereof Pending 02-May-2024
WO-2025229403-A1 Lipid compositions and methods of use thereof Pending 02-May-2024
EP-4731247-A1 Compositions and methods for treating acromegaly Pending 20-Jun-2023 A61K38/31
To view Camurus’s complete patent history, request access »

Camurus Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Camurus Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Camurus‘s full profile, request access.

Request a free trial

Camurus Investments (1)

Camurus’s most recent deal was a Corporate Asset Purchase with Camurus (Octreotide FluidCrystal Product CAM2029). The deal was made on 03-May-2018.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Camurus (Octreotide FluidCrystal Product CAM2029) 03-May-2018 Corporate Asset Purchase Buildings and Property
To view Camurus’s complete investments history, request access »

Ready to get started?

Request a free trial

Camurus ESG

Risk Overview

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view Camurus’s complete esg history, request access »

Camurus Exits (1)

Camurus’s most recent exit was on 03-May-2018 from Camurus (Octreotide FluidCrystal Product CAM2029). The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
Camurus (Octreotide FluidCrystal Product CAM2029) 03-May-2018 Completed
To view Camurus’s complete exits history, request access »

Camurus Affiliates

Subsidiaries (3)

Name Industry Location Year Founded
Camurus Austria Vienna, Austria 2021
Camurus SAS Paris, France 2018
Camurus Ltd Duxford, United Kingdom 2017

Camurus FAQs

  • When was Camurus founded?

    Camurus was founded in 1991.

  • Where is Camurus headquartered?

    Camurus is headquartered in Lund, Sweden.

  • What is the size of Camurus?

    Camurus has 316 total employees.

  • What industry is Camurus in?

    Camurus’s primary industry is Drug Discovery.

  • Is Camurus a private or public company?

    Camurus is a Public company.

  • What is Camurus’s stock symbol?

    The ticker symbol for Camurus is CAMX.

  • What is the current stock price of Camurus?

    As of 13-Nov-2026 the stock price of Camurus is $74.23.

  • What is the current market cap of Camurus?

    The current market capitalization of Camurus is $4.42B.

  • What is Camurus’s current revenue?

    The trailing twelve month revenue for Camurus is $258M.

  • Who are Camurus’s competitors?

    H. Lundbeck, Alvotech, Supernus, Indivior, and Ethypharm are some of the 43 competitors of Camurus.

  • What is Camurus’s annual earnings per share (EPS)?

    Camurus’s EPS for 12 months was $1.35.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process